These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 1905083)

  • 21. Outbreaks of hepatitis A and emergence of new AIDS-associated agents: the need to add terminal 100 degrees C dry-heat sterilization to factor VIII and factor IX concentrates.
    Guillaume TA
    Vox Sang; 1993; 65(2):158. PubMed ID: 8212671
    [No Abstract]   [Full Text] [Related]  

  • 22. Transmission of hepatitis A to patients with hemophilia by factor VIII concentrates treated with organic solvent and detergent to inactivate viruses. The Italian Collaborative Group.
    Mannucci PM; Gdovin S; Gringeri A; Colombo M; Mele A; Schinaia N; Ciavarella N; Emerson SU; Purcell RH
    Ann Intern Med; 1994 Jan; 120(1):1-7. PubMed ID: 7504424
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Terminal 100 degrees C dry-heat treatment of intravenous immunoglobulin preparations to assure sterility.
    Rubinstein AI; Rubinstein DB; Tom W
    Vox Sang; 1994; 66(4):295-6. PubMed ID: 8079455
    [No Abstract]   [Full Text] [Related]  

  • 24. Determination of adequate moisture content for efficient dry-heat viral inactivation in lyophilized factor VIII by loss on drying and by near infrared spectroscopy.
    Savage M; Torres J; Franks L; Masecar B; Hotta J
    Biologicals; 1998 Jun; 26(2):119-24. PubMed ID: 9811517
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Evaluation of viral safety of a high-purity human factor VIII concentrate submitted to 2 specific virus inactivation treatments (FANDHI)].
    Ristol P; Gensana M; Fernández J; Massot M; Biescas H; Darling A; Jorquera JI; Vericat F
    Sangre (Barc); 1996 Apr; 41(2):131-6. PubMed ID: 9045353
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Progress in purification of virus-inactivated factor VIII concentrates. Three generations of solvent/detergent treated plasma derivatives.
    Schwinn H; Smith A; Wolter D
    Arzneimittelforschung; 1989 Oct; 39(10):1302-5. PubMed ID: 2514695
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Blood sterilisation with high temperature terminal dry heat.
    Haller JD
    Lancet; 1996 Mar; 347(9004):827-8. PubMed ID: 8622352
    [No Abstract]   [Full Text] [Related]  

  • 28. Modification of factor VIII in therapeutic concentrates after virus inactivation by solvent-detergent and pasteurisation.
    Raut S; Di Giambattista M; Bevan SA; Hubbard AR; Barrowcliffe TW; Laub R
    Thromb Haemost; 1998 Oct; 80(4):624-31. PubMed ID: 9798982
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Viral safety of a new highly purified factor VIII (OCTATE).
    Biesert L; Lemon S; Goudeau A; Suhartono H; Wang L; Brede HD
    J Med Virol; 1996 Apr; 48(4):360-6. PubMed ID: 8699169
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Severe heat treatment of freeze-dried coagulation factor concentrates: is hotter necessarily better?
    Roberts PL
    Vox Sang; 1995; 68(1):61-2. PubMed ID: 7725674
    [No Abstract]   [Full Text] [Related]  

  • 31. Treatment of type III von Willebrand's disease with solvent/detergent-treated factor VIII concentrates.
    Gazengel C; Fischer AM; Schlegel N; Rothschild C; Torchet MF; Dautzenberg MD; Aujard Y
    Nouv Rev Fr Hematol (1978); 1988; 30(4):225-7. PubMed ID: 3143100
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Virus inactivation in plasma fractions for therapeutic use].
    Burnouf T; Martinache L; Goudemand M
    Nouv Rev Fr Hematol (1978); 1987; 29(1):93-6. PubMed ID: 3588282
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characteristics of the von Willebrand factor in virus inactivated F VIII concentrates: the impact of heat treatment.
    Ingerslev J; Bukh A; Wallevik K; Møller NP; Stenbjerg S
    Thromb Res; 1987 Jul; 47(2):175-82. PubMed ID: 3116714
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Detection of factor VIII and IX inhibitors after first exposure to heat-treated concentrates.
    Hasegawa DK; Edson JR
    Lancet; 1987 Feb; 1(8530):449. PubMed ID: 2880242
    [No Abstract]   [Full Text] [Related]  

  • 35. Heat inactivation of human immunodeficiency virus in lyophilized factor VIII and factor IX concentrates.
    Piszkiewicz D; Bourret L; Lieu M; Hattley K; Thomas W; Cabradilla CD; Kingdon H; Menache D
    Thromb Res; 1987 Jul; 47(2):235-41. PubMed ID: 3116716
    [No Abstract]   [Full Text] [Related]  

  • 36. Virus safety of pooled fresh-frozen plasma inactivated by solvent/detergent treatment.
    Prince AM; Horowitz B
    Beitr Infusionsther; 1993; 31():21-4. PubMed ID: 7693256
    [No Abstract]   [Full Text] [Related]  

  • 37. Heat treatment at 100 degrees C of factor VIII and IX coagulation factor concentrates.
    Teh LC; Woodfield DG
    Med J Aust; 1993 Sep; 159(5):355-6. PubMed ID: 8361441
    [No Abstract]   [Full Text] [Related]  

  • 38. Comparison of the in vitro characteristics of von Willebrand factor in British and commercial factor VIII concentrates.
    Lawrie AS; Harrison P; Armstrong AL; Wilbourn BR; Dalton RG; Savidge GF
    Br J Haematol; 1989 Sep; 73(1):100-4. PubMed ID: 2508742
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics and acute tolerance of a double virus inactivated plasma derived factor VIII concentrate.
    Saez A; Bosh N; Boadas N; Arguello A; Horvat D; Dinapoli G; Lisciani R
    Haemophilia; 1999 Jul; 5(4):260-5. PubMed ID: 10469180
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro characterization of various factor VIII concentrates.
    Yoshioka A; Shima M; Nishino M; Yoshikawa N; Fukui H
    Arzneimittelforschung; 1987 Jul; 37(7):753-6. PubMed ID: 3118888
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.